Mrinal Patnaik
@MrinalPatnaik
Followers
4K
Following
9K
Media
171
Statuses
2K
Director Precision Genomics Clinic, Chronic Myelomonocytic Leukemia Epigenetics lab, Hematology, Mayo Clinic, Minnesota. 🇮🇳🇺🇸GSD and 🎾🏏fan for life!
Minnesota, USA
Joined August 2019
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis | Nature Communications 1100 #CMML cases with #WES #NGS #RNAseq #ChIPseq #DIPseq - #MPNCMML is a #Rasopathy. #JAK2CMML with unique biology @MayoCancerCare
nature.com
Nature Communications - Chronic myelomonocytic leukaemia is classified as proliferative (pCMML) or dysplastic based on the white blood cell counts but biological differences are unclear. Here, the...
3
27
94
Clonal haematopoiesis to clonal cytopenias: unravelling disease evolut. @TheLancetHaem Kristina Kirschner Yael Kusne Catherine Cargo #CH #CCUS #Agerelated #Contextrelevant @MayoCancerCare @MayoClinic.
0
3
12
RT @pnatarajanmd: Delighted to collaborate on this study led by @jieliu09 @KellyLBolton describing how germline genetic variation influence….
0
16
0
RT @ccsizmar: When it comes to TET2 mutations in CMML, more are better! Multiple TET2 mt offset the negative impacts of ASXL1 and RAS mutat….
0
5
0
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia - PubMed @MDAndersonNews @MayoCancerCare @BloodPortfolio GMB @sanamloghavi @doctorpemm @ccsizmar #CMML #RAS
pubmed.ncbi.nlm.nih.gov
RAS pathway mutations (RASMT) induce proliferative features and promote transformation in chronic myelomonocytic leukemia (CMML). However, the unique clonal landscape and hierarchy of distinct RASMT...
1
10
31
RAS Mutation Identifies a Poor Prognostic Molecular Subtype of Therapy-Related Myeloid Neoplasm - PubMed @MayoCancerCare #RAS
pubmed.ncbi.nlm.nih.gov
RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm
0
4
19
RT @bloodgenes: Delighted to have our work on Polygenic Modifiers of #TelomereBiologyDisorders, led by @michaelpoeschla, along with @SashaG….
0
29
0
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia #CMML #TET2 @ccsizmar @MayoCancerCare @MDAndersonNews
pubmed.ncbi.nlm.nih.gov
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes
3
4
26
RT @DavidSteensma: With the disappointing announcement today by @abbvie of the negative result of the VERONA venetoclax/azacitidine trial,….
0
80
0
RT @TalhaBadarMD: #EHA2025 #EHA25 #PPM1D #TP53 .Do visit our poster, highlighting the prevalence and clinical correlates of PPM1Dm in thera….
0
4
0
RT @sanamloghavi: stop by our poster this eve at #EHA2025 PS1620 .@GMontalbanBravo will present our work on refining the Dx criteria for O….
0
7
0
RT @doctorveera: A striking example of human genetics-driven molecular discovery. A GWAS of Yersinia pestis infection in 1,000 B cell lines….
0
20
0
RT @LudovicaMarando: Thrilled to begin a new chapter at BCM!.Alongside developing a CHIP clinic, I will continue research on how CH becomes….
0
4
0
A mutant ASXL1-BAP1-EHMT complex contributes to heterochromatin dysfunction in clonal hematopoiesis and chronic mon… #CH #CMML #ASXL1.
pubmed.ncbi.nlm.nih.gov
ASXL transcriptional regulator 1 (ASXL1) is one of the three most frequently mutated genes in age-related clonal hematopoiesis (CH), alongside DNA methyltransferase 3 alpha (DNMT3A) and Tet methylc...
0
1
15
Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk? @MayoClinic.
pubmed.ncbi.nlm.nih.gov
Peptide receptor radionuclide therapy (PRRT) with lutetium-177-Dotatate (177Lu-DOTATATE) has transformed neuroendocrine tumor (NET) treatment, improving progression-free survival, symptom control,...
0
1
5
Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome. #CH #CCUS #R525H.
pubmed.ncbi.nlm.nih.gov
Germline variants in DDX41 (DDX41MT-germline predisposition syndrome [GPS]) are associated with predisposition to haematological malignancies (HM), including lymphoid and myeloid neoplasms (MN). We...
0
9
36
RT @Aiims1742: The FY26 HHS Budget in Brief has been released. It outlines how the existing NIH institutes & centers will be combined into….
0
39
0
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific membrane antigen therapy #Lutetium #CH #PPM1D #TP53 #prostate @Yael_Kusne @MayoCancerCare.
pubmed.ncbi.nlm.nih.gov
Not available.
1
4
21
RT @VJHemOnc: Watch our interview with @MrinalPatnaik (@MayoClinic) from #IBC2025 to learn about the difference between age-related clonal….
vjhemonc.com
Mrinal Patnaik, MBBS, Mayo Clinic, Rochester, MN, comments on the distinction between age-related clonal hematopoiesis (CH) and context-relevant CH, highlighting that the latter is more frequently...
0
9
0
RT @matteolambe: Just published in @JCO_ASCO the updated @ASCO guidelines on fertility preservation in people with #cancer: a must read for….
0
199
0